Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

被引:195
作者
Honma, Naoko [1 ]
Horii, Rie
Iwase, Takuji
Saji, Shigehira
Younes, Mamoun
Takubo, Kaiyo
Matsuura, Masaaki
Ito, Yoshinori
Akiyama, Futoshi
Sakamoto, Goi
机构
[1] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Dis, Itabashi Ku, Tokyo 1730015, Japan
关键词
D O I
10.1200/JCO.2007.14.2968
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The clinicopathologic importance of a second estrogen receptor (ER), ER-beta, in breast cancers has been intensely studied; however, there is still no real consensus regarding the clinical utility of an ER-beta assay, probably because of the lack of standardized methodology, the presence of several ER-beta isotypes (ER-beta 1-5, and so on), and, more importantly, the lack of convincing data on whether the ER-beta status provides clinically useful information over what is already provided by the traditional ER-alpha/progesterone receptor (PR) assay. A large and systematic study is needed to address these important issues. Patients and Methods Archival materials of 442 invasive breast cancers from women treated with adjuvant tamoxifen monotherapy and with a long follow-up period (median, 11.1 years) were subjected to immunohistochemical study using three commercially available anti -ER-beta antibodies that detect ER-beta 1-3 (ER-beta N), ER-beta 1, and ER-beta cx wwER-beta 2). Results Positive staining for ER-beta N or ER-beta 1 was associated with significantly better survival. By contrast, ER-beta cx status did not influence survival. In multivariate analysis, ER-beta 1 status emerged as an independent predictor of recurrence and mortality. ER-beta 1 status was significantly associated with survival in postmenopausal, but not premenopausal, women. Importantly, ER-beta 1 positivity was associated with significantly better survival in patients with ER-alpha-negative/PR-negative or ER-alpha-negative/PR-negative/human epidermal growth factor receptor 2 -negative wwtriple-negative) tumors, which are widely believed to be hormone unresponsive, have poor prognosis, and require chemotherapy. Conclusion Immunohistochemical examination of ER-beta 1 in addition to ER-alpha and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy. Further studies are needed to confirm our findings.
引用
收藏
页码:3727 / 3734
页数:8
相关论文
共 42 条
[1]  
Allred DC, 1998, MODERN PATHOL, V11, P155
[2]   Estrogen receptor α and β profiling in human breast cancer [J].
Balfe, P ;
McCann, A ;
McGoldrick, A ;
McAllister, K ;
Kennedy, M ;
Dervan, P ;
Kerin, MJ .
EJSO, 2004, 30 (05) :469-474
[3]  
Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0
[4]   Triple-negative breast cancer: therapeutic options [J].
Cleator, Susan ;
Heller, Wolfgang ;
Coombes, R. Charles .
LANCET ONCOLOGY, 2007, 8 (03) :235-244
[5]  
*EARL BREAST CANC, 1992, LANCET, V339, P1
[6]   Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer [J].
Esslimani-Sahla, M ;
Simony-Lafontaine, J ;
Kramar, A ;
Lavaill, R ;
Mollevi, C ;
Warner, M ;
Gustallsson, JÅ ;
Rochefort, H .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5769-5776
[7]  
Fuqua SAW, 2003, CANCER RES, V63, P2434
[8]   Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma [J].
Gruvberger-Saal, Sofia K. ;
Bendahl, Paer-Ola ;
Saal, Lao H. ;
Laakso, Mervi ;
Hegardt, Cecilia ;
Eden, Patrik ;
Peterson, Carsten ;
Malmstroem, Per ;
Isola, Jorma ;
Borg, Ake ;
Fernoe, Marten .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :1987-1994
[9]   Estrogen receptor β inhibits angiogenesis and growth of T47D breast cancer xenografts [J].
Hartman, Johan ;
Lindberg, Karolina ;
Morani, Andrea ;
Inzunza, Jose ;
Strom, Anders ;
Gustafsson, Jan-Ake .
CANCER RESEARCH, 2006, 66 (23) :11207-11213
[10]   Expression of oestrogen receptor-β in apocrine carcinomas of the breast [J].
Honma, N. ;
Takubo, K. ;
Akiyama, F. ;
Kasumi, F. ;
Sawabe, M. ;
Arai, T. ;
Hosoi, T. ;
Yoshimura, N. ;
Harada, N. ;
Younes, M. ;
Sakamoto, G. .
HISTOPATHOLOGY, 2007, 50 (04) :425-433